Rising demand for effective weight reduction strategies and improved glycemic control, especially in regions facing surging rates of metabolic disorders, is a key factor driving market expansion
The primary endpoint - MASH improvement absent fibrosis progression - was observed in 47%, 62%, and 43% of the 2.4, 4.8, and vs
While not as dramatic as trial results, this shift can still be significant for individuals struggling with weight
Further understanding of the complex mechanisms that regulate metabolic homeostasis and how these become dysregulated during metabolic diseases, which are currently a major global burden, will likely lead to the development of new highly desirable more effective therapeutic strategies to combat metabolic diseases such as T2D
[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated
This steady digestion supports a gradual glucose release, encouraging continuous GLP-1 secretion
